Table 1 Baseline characteristics of study participants
Parameter | Ipragliflozin (n = 77) | Sitagliptin (n = 83) | P* | ||
|---|---|---|---|---|---|
n | % | n | % | ||
Male | 44 | 57.1 | 44 | 53.0 | 0.64 |
Current smoking | 20 | 26.0 | 21 | 25.3 | 1.00 |
Current drinking | 35 | 45.5 | 44 | 53.0 | 0.35 |
Comorbidity | Â | Â | Â | Â | Â |
 Diabetic retinopathy | 1 | 1.3 | 2 | 2.4 | 1.00 |
 Diabetic nephropathy | 13 | 16.9 | 15 | 18.1 | 1.00 |
 Dyslipidemia | 56 | 72.7 | 60 | 72.3 | 1.00 |
 Hypertension | 62 | 80.5 | 50 | 60.2 | 0.006 |
 Hyperuricemia | 13 | 16.9 | 13 | 15.7 | 1.00 |
 Liver disease | 7 | 9.1 | 8 | 9.6 | 1.00 |
 Coronary artery disease | 2 | 2.6 | 3 | 3.6 | 1.00 |
 Arteriosclerosis obliterans | 4 | 5.2 | 3 | 3.6 | 0.71 |
Past medical history | Â | Â | Â | Â | Â |
 Malignant neoplasm | 4 | 5.2 | 1 | 1.2 | 0.20 |
 Myocardial infarction | 1 | 1.3 | 0 | 0.0 | 0.48 |
 Stroke | 1 | 1.3 | 0 | 0.0 | 0.48 |
 Heart failure | 0 | 0.0 | 0 | 0.0 | - |